

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/973,142	BIEDIGER ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Celia Chang	1625	

-- *The MAILING DATE of this communication appears on the cover sheet with the correspondence address--*

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 11/15/04.
2.  The allowed claim(s) is/are 12,14,15 and 32-36.
3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All      b)  Some\*    c)  None    of the:
    1.  Certified copies of the priority documents have been received.
    2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
  6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
    - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
      - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
    - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date attached.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

  
 Celia Chang  
 Primary Examiner  
 Art Unit 1625

### **DETAILED ACTION**

1. Amendment and response filed by applicants dated Nov. 10, 2004 have been entered and considered carefully. Claims 6, 9, 13, 16, 18, have been canceled. Claims 20-24, 27-29 stayed withdrawn. The erroneous withdrawn of claim 26 is hereby re-instated as pending.

2. *Examiner's Amendment*

Authorization for this examiner's amendment was given in a telephone interview with Mr. Martin Katz on Mar 17, 2005.

Claims 1-11, 17, 19-24, 27, 29 and 25 in part, being drawn to the nonelected inventions are canceled without prejudice against applicant's filing of divisional applications.

Claims 25, 26, 28, 30 and 31 are canceled and replaced with the following:

**Claim 32.** (new) A compound selected from the group consisting of

(3S)-3-(1,3-benzodioxol-5-yl)-3-[{[2-oxo-1-(phenylmethyl)-4-propyl-1,2-dihydro-3-pyridinyl]amino}carbonyl]amino]propanoic acid,

(3S)-3-{[(1-[(2-chlorophenyl)methyl]-4-ethyl-2-oxo-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{[(1-[(2-chlorophenyl)methyl]-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{[(6-methyl-2-oxo-1-(phenylmethyl)-4-[(phenylmethyl)oxy]-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{[(4-amino-1-[(2-chlorophenyl)methyl]-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{[(1-[(2-chlorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-[4-(methyloxy)phenyl]propanoic acid,

(3S)-3-{[(1-[(2-chlorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(3,4-dimethylphenyl)propanoic acid,

(3S)-3-{[(4-amino-1-[(2-chlorophenyl)methyl]-2-oxo-1,2-dihydro-3-pyridinyl)amino]carbonyl}amino}-3-(4-methylphenyl)propanoic acid,

Art Unit: 1625

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-(1,4-oxazinan-4-yl)-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-2-oxo-4-(propylamino)-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-bromophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-[3-methyl-4-(methyloxy)phenyl] propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-2-oxo-4-phenyl-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-[(2-{[2-(methyloxy)ethyl]oxy} ethyl)oxy]-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-[(1,1-dimethylethyl)amino]-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-phenylpropanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-[4-methyltetrahydro-1(2H)-pyrazinyl]-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(4-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-[4-(methyloxy)phenyl] propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(3,5-dimethylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-(3-methylphenyl) propanoic acid,

(3S)-3-{{({1-[{(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl} amino} carbonyl) amino}-3-[3-(methyloxy)phenyl] propanoic acid,

Art Unit: 1625

(3S)-3-[3,5-bis(methyloxy)phenyl]-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}propanoic acid,

(3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-[3-(trifluoromethyl)phenyl]propanoic acid,

(3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[(ethyl[(ethylamino)carbonyl]amino}carbonyl]amino}-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{{{{4-(1-azetanyl)-1-[(2-chlorophenyl)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-[[{{1-[(2-chlorophenyl)methyl]-4-[(2-[(2-[(2-methyloxy)ethyl]oxy)ethyl]oxy]ethyl]oxy}-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-{{{{1-[(2-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{{{{1-[(2-chloro-6-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{{{{1-[(2-chlorophenyl)methyl]-5-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-(1,3-benzodioxol-5-yl)-3-(((2-oxo-1-((4-(trifluoromethyl)phenyl)methyl)-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)propanoic acid,

(3S)-3-((((1-((2-chlorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid,

(3S)-3-((((1-((2-fluorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid,

(3S)-3-((((1-((2-bromophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid,

(3S)-3-((((1-((2,4-dichlorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid,

(3S)-3-((((1-((2-chloro-6-fluorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid,

(3S)-3-(((1-((2-chlorophenyl)methyl)-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-trifluoromethyl)oxy)phenyl)propanoic acid,  
(3S)-3-[([1-(2-chloro-6-methoxybenzyl)-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
4-{[3-[({(1S)-2-carboxy-1-(4-methylphenyl)ethyl}amino} carbonyl)amino]-1-(2-chlorobenzyl)-2-oxo-1,2-dihdropyridin-4-yl]amino}benzoic acid,  
(3S)-3-{[({1-(2-chlorobenzyl)-4-[(2,2-dimethylpropanoyl)amino]}-2-oxo-1,2-dihdropyridin-3-yl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[4-[(tert-butylamino)carbonyl]amino}-1-(2-chlorobenzyl)-2-oxo-1,2-dihdropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(7-methoxy-1,3-benzodioxol-5-yl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxy-4-methoxyphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-dimethoxyphenyl)propanoic acid,  
(3S)-3-[({[1-(4-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chloro-6-methoxybenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2,6-difluorobenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,  
(3S)-3-[({[1-(2-chloro-6-methoxybenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3,5-dimethoxyphenyl)propanoic acid,

Art Unit: 1625

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3,4-diethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3-methoxy-4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3,5-dimethoxy-4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3,4-dimethylphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-5-ethyl-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-{([([1-[2-chloro-5-(trifluoromethyl)benzyl]-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-methoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-methylbenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2,6-dimethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3-propoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-5-propyl-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-5-propyl-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]-3-(3,4-diethoxyphenyl)propanoic acid,

(3S)-3-(3-butoxyphenyl)-3-[([1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino)carbonyl]amino]propanoic acid,

Art Unit: 1625

(3S)-3-{[(1-[2-chloro-5-(methylsulfonyl)benzyl]-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl}amino]carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-[3-(2-methoxyethoxy)phenyl]propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3,4-dipropoxypyhenyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-[3-(difluoromethoxy)phenyl]propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3,4-diethoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chloro-6-methylbenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3,4-diethoxyphenyl)propanoic acid,

3-{[(1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(2-naphthyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3,4-diethoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chloro-6-methoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3,4-diethoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3-isopropoxypyhenyl)propanoic acid,

(3S)-3-{[(1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(4-methoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-{[(1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(3-isopropoxypyhenyl)propanoic acid,

(3S)-3-{[(1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl]amino}-3-(1-methyl-1H-indol-5-yl)propanoic acid,

Art Unit: 1625

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid,

(3S)-3-[([5-chloro-1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphe nyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-[3-(trifluoromethoxy)phenyl]propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphe nyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-5-cyclopropyl-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphe nyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-5-cyclopropyl-4-hydroxy-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-5-methoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-6-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphe nyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(1-methyl-1H-indol-6-yl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-(6-methoxy-2-naphthyl)propanoic acid,

(3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihdropyridin-3-yl]amino} carbonyl)amino]-3-[3-(diethylamino)phenyl]propanoic acid,

Art Unit: 1625

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid;;

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid,

(3S)-3-[([1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(6-methoxy-2-naphthyl)propanoic,

and pharmaceutically acceptable salts thereof.

**Claim 33.** (3S)-3-[([1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl}amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid and pharmaceutical acceptable salts thereof.

**Claim 34.** (3S)-3-[([1-(2-chlorobenayl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-[3-(diethylamino)phenyl]propanoic acid and pharmaceutically acceptable salts thereof.

**Claim 35.** A pharmaceutical composition comprising an effective amount of a compound selected from one of claims 12, 14, 15, 32, 33 or 34 and a pharmaceutically acceptable carrier.

**Claim 36.** A method for treating asthma, multiple sclerosis or inflammatory bowel diseases in a mammal comprising administering to said mammal a therapeutically effective amount of a compound selected form one of claims 12, 14, 15, 32, 33, or 34.

3.

***Reason for Allowance***

The following is an examiner's statement of reasons for allowance:

Applicants have limited the claims to the elected invention of claims 12, 14, 15, and newly limited claims 32-36. The elected claims being drawn to the small genus of dihydropyridinyl compounds which displayed similar RAMOS cell assay activity in analogous compounds (see CA 135:33648) for treating asthma, multiple sclerosis or inflammatory bowel diseases (see p. 2 specification). Claims 12, 14, 15, 32-36 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang  
Mar. 17, 2005

  
Celia Chang  
Primary Examiner  
Art Unit 1625